The first blood test that will help diagnose her Alzheimer’s disease It will be available from the end of June in the US after the green light of the authorities, according to the Japanese company behind innovation.

The examination will initially be available in about 50 US research institutions and hospitals specializing in Alzheimer’s disease, Tuesday said in an interview with Goki Ishikawahead of it Fujirebio Diagnostics Inc that developed the exam.

The company, a subsidiary of Japanese HU Group Holdings Inc, is also working with larger competitors, such as Beckman Coulter Inc to help develop and manufacture its products, he said.

The Food and Drug Administration (Fda) Approved a blood test that helps diagnose Alzheimer’s disease last week, possibly facilitating the finding and treatment of patients with the disease that affects almost 7 million Americans.

The examination was approved for use by at least 55 years of age who show signs of the disease. It is designed to detect amyloid, a protein that can accumulate in the brain and is a feature of Alzheimer’s disease, the most common form of dementia in the elderly.

The procedure, which takes about 30 minutes from blood to diagnose, will be available in patients at a fraction of a pet scan. The method is considered a critical step to make widely accessible new forms of treatment for Alzheimer’s treatment.

Until now, patients usually have to do a specialized Pet Scan for the detection of amyloid in their brain or undergo cerebrospinal fluid tests, which are both more expensive and invasive. The lack of fast and easy tests has so far slowed the circulation of new drugs for Alzheimer’s.

The company plans to submit data to seek approvals to Japan since August and in Europe this year, Ishaikawa said.

In China, Fujirebio’s unknown partner will probably submit data to the regulatory authorities next year, he added. In India, she works with Agappe Diagnostics Ltd.

“We have a presence in Japan, but this is not necessarily the case in foreign markets,” Ishikawa said. “We cannot get our market shares, but if we supply the raw materials to our partners, we can benefit through them.”